The company's product candidates target the eIF4F complex and its activating kinase, MNK 1/2, which are central nodes where frequently mutated signaling pathways in cancer converge to activate the translation of select mRNA into proteins. Each product candidate is designed to act on a single protein that regulates the expression of multiple functionally related proteins, controlling tumor growth, survival, and immune evasion. eFFECTOR's lead product candidate, tomivosertib, is a MNK 1/2 inhibitor, and the company has a global collaboration with Pfizer to develop inhibitors of a third target, eIF4E. The company has ongoing clinical trials for tomivosertib and zotatifin, an inhibitor of eIF4A.